Tirzepatide
Also known as: Mounjaro · Zepbound · LY3298176
Contents
MW
4813.45 Da
Amino Acids
39 AA
Half-Life
5 days
Route
SubQ
CAS
2023788-19-2
Formula
C225H348N48O68
Mechanism of Action
Tirzepatide is a synthetic 39-amino acid dual GLP-1/GIP receptor agonist. FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). It has a C20 fatty acid chain enabling albumin binding for once-weekly dosing.
GLP-1R ACTIVATION: Appetite suppression, glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay — same mechanisms as semaglutide.
GIPR ACTIVATION (Unique vs Semaglutide): GIP receptor activation potentiates insulin secretion beyond GLP-1 alone, promotes adipose tissue remodeling (improved fat distribution), and may enhance lipid handling. The addition of GIPR agonism produces greater metabolic improvements than GLP-1 alone.
CLINICAL RESULTS: SURMOUNT-1 trial showed 22.5% body weight loss at 72 weeks with 15 mg tirzepatide — exceeding semaglutide's STEP 1 results (14.9%). SURPASS trials showed HbA1c reductions of 2.0–2.6% in T2D — also exceeding semaglutide.
The dual agonist approach (GLP-1 + GIP) appears to produce superior weight loss and glycemic control compared to GLP-1 alone.
Dosing Protocol
Low Dose
███ – ███ mcg/day
Standard Dose
███ mcg/day
High Dose
███ – ███ mcg/day
Dosing protocols are for paid members
Get exact dosing ranges, injection frequency, timing rationale, and reconstitution math.
Get Clinical Access — $79/moFrequency
Once weekly SubQ.
Half-Life
5 days
Reconstitution Guide
Full reconstitution protocol with BAC water volumes, concentration math, and units-to-draw per dose is available on the Clinical plan.
Unlock reconstitution guide →Clinical Warnings
Same class warnings as semaglutide: thyroid C-cell tumors (rodent), pancreatitis, gallbladder disease, AKI from dehydration.
GI side effects common during escalation.
Muscle loss with rapid weight loss.
Injection site reactions.
Very expensive.
Contraindications
Absolute
Personal or family history of medullary thyroid cancer
MEN2 syndrome
Pregnancy
Pancreatitis
Relative Cautions
Type 1 diabetes
Gastroparesis
Gallbladder disease
Severe renal impairment
Side Effect Profile
Mild
- ●Nausea
- ●Diarrhea
- ●Decreased appetite
Moderate
- ●Vomiting
- ●Constipation
- ●Abdominal pain
- ●Dyspepsia
Severe (Rare)
- ●Pancreatitis
- ●Thyroid C-cell tumors (boxed warning)
- ●Severe hypoglycemia
Synergistic Peptides
Common Stacks
Semaglutide
Retatrutide
Research Status
FDA APPROVED. PMID 35905167 (Jastreboff 2022 NEJM — SURMOUNT-1): 22.5% weight loss at 72 weeks. PMID 34170647 (Ludvik 2021 Lancet — SURPASS-3): HbA1c -2.37%. Multiple Phase III trials completed.
Frequently Asked Questions
How does Tirzepatide work?
Tirzepatide is a synthetic 39-amino acid dual GLP-1/GIP receptor agonist. FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). It has a C20 fatty acid chain enabling albumin binding for once-weekly dosing. GLP-1R ACTIVATION: Appetite suppression, glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay — same mechanisms as semaglutide. GIPR ACTIVATION (Unique vs Semaglutide): GIP receptor activation potentiates insulin secretion beyond GLP-1 alone, promot
What is the standard dose of Tirzepatide?
Tirzepatide dosing protocols are available with a ClinPep Clinical subscription. Dosing varies by indication and patient factors — consult a licensed healthcare provider. General frequency: Once weekly SubQ.
What is the half-life of Tirzepatide?
The half-life of Tirzepatide is 5 days. This determines optimal dosing frequency and timing.
Who should not use Tirzepatide?
Tirzepatide is absolutely contraindicated in: Personal or family history of medullary thyroid cancer; MEN2 syndrome; Pregnancy; Pancreatitis. Use with caution in: Type 1 diabetes; Gastroparesis; Gallbladder disease.
What are the side effects of Tirzepatide?
Common mild side effects include: Nausea, Diarrhea, Decreased appetite. Moderate effects: Vomiting, Constipation, Abdominal pain, Dyspepsia.
What peptides stack well with Tirzepatide?
Tirzepatide is commonly stacked with: Semaglutide, Retatrutide, AOD-9604.
How do you reconstitute Tirzepatide?
Tirzepatide is reconstituted with bacteriostatic water. Exact volumes, concentrations, and units-to-draw calculations are available in the ClinPep Clinical plan. Always follow your compounding pharmacy's instructions.
How long should you cycle Tirzepatide?
Tirzepatide cycle protocols vary by indication. Detailed cycle length, on/off schedules, and monitoring guidelines are available with ClinPep Clinical access. Consult your healthcare provider for personalized cycling guidance.
References & Citations
10 PubMed studies · 3 clinical trials
Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease.
Kazi Muhammad Ali Ibrahim, Singh Sanmeet, Haq Nowreen. Journal of clinical medicine. 2025
Background: Patients with type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) face elevated risk of hepatobiliary complications. The biliary safety of GLP-1 and dual GLP-1/GIP recepto
Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.
Hiraide Takahiro, Suzuki Yoshihiko, Yamamoto Satoko, Yagihashi Soroku et al.. Journal of health, population, and nutrition. 2025
Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, has demonstrated robust efficacy in clinical trials; however, discontinuation rates due to gastrointestinal adverse events have been reported
Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage.
DesRochers Peter, Kaiser Linus, Lee Seoyoon, Perchetti Garrett A et al.. Cureus. 2025
The prevalence of type 2 diabetes mellitus has increased drastically over the past century. In the past few years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have gained significant popularity
Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.
Ma Jun, Tao Mengyuan, Zhang Wencheng, Zhou Li et al.. Frontiers in molecular biosciences. 2025
This study evaluated the effect of Tirzepatide on metabolic profiles, kidney function, and gut microbiota composition in mice with diabetic kidney disease (DKD) and clarify the relationship between gu
Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.
Davila Diaz Rodrigo, Campos Barrera Eugenia, Diaz Fosado Luis Alfonso, Reyes Esparza Arturo et al.. Cureus. 2025
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among plastic surgery patients for obesity and overweight. Agents such as dulaglutide, liraglutide, semaglutide, and t
Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.
Suresh Babu Yashwanth, Jayagopal Vijay. Cureus. 2025
Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in adults with cystic fibrosis (CF). Traditional management relied on insulin therapy to counter the rise in glucose related to a
Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.
Duncan Jessica, Stevens Patrick Lee, Bigby Emily, Floyd Courtney et al.. Obesity pillars. 2026
Obesity and its downstream effects continue to drive rising rates of chronic disease. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) recepto
An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription.
Sathambihai Thibagaran, Mathur Kushagra, Siddavaram Seshnag. Cureus. 2025
Obesity affects a significant proportion of the UK population, and tirzepatide, a dual glucagon-like peptide (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist, is increasingly being pr
Registered Clinical Trials
Study of Patients Being Treated With Anti-obesity Medication
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Symptom Indications
Full Clinical Access
Complete Tirzepatide Protocol
Access reconstitution math, cycle guides, drug interaction checker, stack builder with contraindication analysis, symptom checker, and downloadable PDF handouts.
Secure payment powered by Stripe.
This information is for educational and research reference purposes only. ClinPep does not provide medical advice, diagnosis, or treatment recommendations. All protocols should be reviewed by a licensed healthcare provider.